Interrogating the precancerous evolution of pathway dysfunction in lung squamous cell carcinoma using XTABLE

  1. Matthew Roberts
  2. Julia Ogden
  3. A S Md Mukarram Hossain
  4. Anshuman Chaturvedi
  5. Alastair RW Kerr
  6. Caroline Dive
  7. Jennifer Ellen Beane
  8. Carlos Lopez-Garcia  Is a corresponding author
  1. University of Manchester, United Kingdom
  2. Cancer Research UK Manchester Institute, United Kingdom
  3. The Christie Hospital, United Kingdom
  4. Boston University, United States

Abstract

Lung squamous cell carcinoma (LUSC) is a type of lung cancer with a dismal prognosis that lacks adequate therapies and actionable targets. This disease is characterized by a sequence of low and high-grade preinvasive stages with increasing probability of malignant progression. Increasing our knowledge about the biology of these premalignant lesions (PMLs) is necessary to design new methods of early detection and prevention, and to identify the molecular processes that are key for malignant progression. To facilitate this research, we have designed XTABLE, an open-source application that integrates the most extensive transcriptomic databases of PMLs published so far. With this tool, users can stratify samples using multiple parameters and interrogate PML biology in multiple manners, such as two and multiple group comparisons, interrogation of genes of interests and transcriptional signatures. Using XTABLE, we have carried out a comparative study of the potential role of chromosomal instability scores as biomarkers of PML progression and mapped the onset of the most relevant LUSC pathways to the sequence of LUSC developmental stages. XTABLE will critically facilitate new research for the identification of early detection biomarkers and acquire a better understanding of the LUSC precancerous stages.

Data availability

The current manuscript makes use of previously published databases, so no data have been generated for this manuscript. All analyses shown in the manuscript has been carried out using XTABLE and can be reproduced easily by any user.

The following previously published data sets were used

Article and author information

Author details

  1. Matthew Roberts

    Cancer Biomarker Centre, University of Manchester, Alderley Edge, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  2. Julia Ogden

    Cancer Research UK Manchester Institute, Alderley Edge, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  3. A S Md Mukarram Hossain

    Cancer Biomarker Centre, University of Manchester, Alderley Edge, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  4. Anshuman Chaturvedi

    Department of Histopathology, The Christie Hospital, Manchester, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  5. Alastair RW Kerr

    Cancer Biomarker Centre, University of Manchester, Edinburgh, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-9207-6050
  6. Caroline Dive

    Cancer Biomarker Centre, University of Manchester, Alderley Edge, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  7. Jennifer Ellen Beane

    School of Medicine, Boston University, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.
  8. Carlos Lopez-Garcia

    Cancer Research UK Manchester Institute, Alderley Edge, United Kingdom
    For correspondence
    carlos.lopezgarcia@cruk.manchester.ac.uk
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-9848-8216

Funding

Cancer Research UK (A25146)

  • Julia Ogden
  • A S Md Mukarram Hossain
  • Anshuman Chaturvedi
  • Alastair RW Kerr
  • Caroline Dive
  • Carlos Lopez-Garcia

Manchester Biomedical Research Centre

  • Matthew Roberts

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2023, Roberts et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,048
    views
  • 145
    downloads
  • 3
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Matthew Roberts
  2. Julia Ogden
  3. A S Md Mukarram Hossain
  4. Anshuman Chaturvedi
  5. Alastair RW Kerr
  6. Caroline Dive
  7. Jennifer Ellen Beane
  8. Carlos Lopez-Garcia
(2023)
Interrogating the precancerous evolution of pathway dysfunction in lung squamous cell carcinoma using XTABLE
eLife 12:e77507.
https://doi.org/10.7554/eLife.77507

Share this article

https://doi.org/10.7554/eLife.77507

Further reading

    1. Cancer Biology
    2. Cell Biology
    Maojin Tian, Le Yang ... Peiqing Zhao
    Research Article

    TIPE (TNFAIP8) has been identified as an oncogene and participates in tumor biology. However, how its role in the metabolism of tumor cells during melanoma development remains unclear. Here, we demonstrated that TIPE promoted glycolysis by interacting with pyruvate kinase M2 (PKM2) in melanoma. We found that TIPE-induced PKM2 dimerization, thereby facilitating its translocation from the cytoplasm to the nucleus. TIPE-mediated PKM2 dimerization consequently promoted HIF-1α activation and glycolysis, which contributed to melanoma progression and increased its stemness features. Notably, TIPE specifically phosphorylated PKM2 at Ser 37 in an extracellular signal-regulated kinase (ERK)-dependent manner. Consistently, the expression of TIPE was positively correlated with the levels of PKM2 Ser37 phosphorylation and cancer stem cell (CSC) markers in melanoma tissues from clinical samples and tumor bearing mice. In summary, our findings indicate that the TIPE/PKM2/HIF-1α signaling pathway plays a pivotal role in promoting CSC properties by facilitating the glycolysis, which would provide a promising therapeutic target for melanoma intervention.

    1. Cancer Biology
    2. Chromosomes and Gene Expression
    Ananda Kishore Mukherjee, Subhajit Dutta ... Shantanu Chowdhury
    Research Article

    Telomeres are crucial for cancer progression. Immune signalling in the tumour microenvironment has been shown to be very important in cancer prognosis. However, the mechanisms by which telomeres might affect tumour immune response remain poorly understood. Here, we observed that interleukin-1 signalling is telomere-length dependent in cancer cells. Mechanistically, non-telomeric TRF2 (telomeric repeat binding factor 2) binding at the IL-1-receptor type-1 (IL1R1) promoter was found to be affected by telomere length. Enhanced TRF2 binding at the IL1R1 promoter in cells with short telomeres directly recruited the histone-acetyl-transferase (HAT) p300, and consequent H3K27 acetylation activated IL1R1. This altered NF-kappa B signalling and affected downstream cytokines like IL6, IL8, and TNF. Further, IL1R1 expression was telomere-sensitive in triple-negative breast cancer (TNBC) clinical samples. Infiltration of tumour-associated macrophages (TAM) was also sensitive to the length of tumour cell telomeres and highly correlated with IL1R1 expression. The use of both IL1 Receptor antagonist (IL1RA) and IL1R1 targeting ligands could abrogate M2 macrophage infiltration in TNBC tumour organoids. In summary, using TNBC cancer tissue (>90 patients), tumour-derived organoids, cancer cells, and xenograft tumours with either long or short telomeres, we uncovered a heretofore undeciphered function of telomeres in modulating IL1 signalling and tumour immunity.